Dr. Alessandro Grattoni is Co-Founder and Chief Scientific Advisor of Continuity Biosciences, and Chair and Professor of the Department of Nanomedicine at Houston Methodist Hospital. His research focuses on implantable nanofluidic platforms for long-term controlled drug delivery, cell transplantation and reprogramming in vivo, with applications in chronic disease treatment and prevention, and regenerative medicine.

Dr. Grattoni established his first collaboration with Continuity’s Executive Chairman, Bob Whitehead, in 2010. Their partnership led to the 2024 licensing of a suite of drug and cell delivery technologies from Houston Methodist. His lab has secured over $40 million in research funding from the NIH, DoD, JDRF, NASA, and private foundations, with additional grants pending.